• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
1AD 0.00% 2.9¢

ADALTA LIMITED

AdAlta Limited is an Australia-based clinical-stage drug discovery company. The Company... AdAlta Limited is an Australia-based clinical-stage drug discovery company. The Company is engaged in the development of therapeutic products from its i-body platform. The Company has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. It develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. It evaluates several CXCR4 i-bodies.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
1AD 24/04/24 122 21K
24/04/24 Last post  Sammyn123 Comments Created with Sketch.  122  Views Created with Sketch.  21K 
1AD 24/04/24 6 722
24/04/24 Last post  DjohnR Comments Created with Sketch.  6  Views Created with Sketch.  722 
1AD 16/04/24 88 14K
16/04/24 Last post  ForeverNewbie Comments Created with Sketch.  88  Views Created with Sketch.  14K 
1AD
News: 1AD Adalta Says Co & Synthesis Bioventures Partner For Development Of Next Generation...
08/04/24 0 146
08/04/24 Last post  Hot News Comments Created with Sketch.  0  Views Created with Sketch.  146 
1AD 08/04/24 0 285
08/04/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  285 
1AD 05/04/24 262 47K
05/04/24 Last post  Beno77 Comments Created with Sketch.  262  Views Created with Sketch.  47K 
1AD 04/04/24 22 5.2K
04/04/24 Last post  debono Comments Created with Sketch.  22  Views Created with Sketch.  5.2K 
1AD 29/03/24 10 3.2K
29/03/24 Last post  Mason14 Comments Created with Sketch.  10  Views Created with Sketch.  3.2K 

See All Discussions arrow Created with Sketch.

Timeline

Notification of Expiry of Listed Options
24 Apr 12:53
 
SYNBV MoU Webinar presentation
10 Apr 08:46
 
Webinar to discuss SYNthesis BioVentures partnership
08 Apr 09:03
 
SYNThesis BioVentures MoU for cellular immunotherapies
08 Apr 08:57
 
AdAlta presenting at ASX Gems conference
20 Mar 08:24
 
Application for quotation of securities - 1AD
15 Mar 11:14
 
View More arrow Created with Sketch.
(20min delay)
Last
2.9¢
Change
0.000(0.00%)
Mkt cap ! $15.24M
Open High Low Value Volume
2.9¢ 2.9¢ 2.9¢ $9.983K 344.2K

Buyers (Bids)

No. Vol. Price($)
1 39713 2.9¢
 

Sellers (Offers)

Price($) Vol. No.
3.0¢ 149915 1
View Market Depth
Last trade - 14.07pm 25/04/2024 (20 minute delay) ?
Last
2.9¢
  Change
0.000 ( 3.57 %)
Open High Low Volume
2.9¢ 2.9¢ 2.9¢ 62033
Last updated 15.43pm 25/04/2024 ?
1AD (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.